<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368211</url>
  </required_header>
  <id_info>
    <org_study_id>CTS-0063</org_study_id>
    <nct_id>NCT01368211</nct_id>
  </id_info>
  <brief_title>Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)</brief_title>
  <acronym>PRESS</acronym>
  <official_title>PRESS Pathogen Reduction Extended Storage Study PRESS (Pathogen Reduction Extended Storage Study) A Pilot Study of Mirasol Platelets Treated in Platelet Additive Solution in Thrombocytopenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo BCTbio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terumo BCTbio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PRESS trial is a single-center, two-part, randomized cross-over pilot study in Copenhagen
      that will evaluate 1) the safety and performance of Mirasol-treated and untreated platelet
      products stored for 2-4 days and for 7-days in Platelet Additive Solution (PAS) and 2) the
      correlation between the TEG® parameters and platelet count increments after platelet
      transfusions in thrombocytopenic subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To evaluate in thrombocytopenic subjects the efficacy and safety of platelets treated
           with Mirasol Pathogen Reduction Technology (PRT) in Platelet Additive Solution. The
           following safety and efficacy measures will be compared between Mirasol treated and
           untreated platelets stored for 2-4 days and stored for 7 days:

             -  Thrombelastography (TEG®) parameters: reaction time R, alpha angle α and maximal
                amplitude (MA)

             -  Platelet Count Increment and Corrected Count Increment

             -  Time to next platelet transfusion

             -  Incidence of transfusion related (serious) adverse events

             -  Incidence and severity of bleedings

        2. To evaluate the use of the TEG® parameters as a measure for platelet transfusion
           efficacy and to evaluate the correlation between the TEG® parameters and the platelet
           Corrected Count Increments after platelet transfusions in thrombocytopenic subjects.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Part 1 completed, part 2 not done due to slow enrollment
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Maximum Amplitude at 1-hour Post-transfusion</measure>
    <time_frame>pre-transfusion, 1-hour post transfusion</time_frame>
    <description>Thromboelastography (TEG) Parameter: Pre- to post-transfusional modification of Maximum Amplitude at 1-hour post-transfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Maximum Amplitude at 24-hours Post-transfusion</measure>
    <time_frame>pre-transfusion, 24-hour post transfusion</time_frame>
    <description>Thromboelastography parameter: Pre- to post-transfusional modification in Maximum Amplitude at 24-hours post-transfusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Mirasol first, then Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This study arm will receive first a 2-4-day-old Mirasol-treated platelets transfusion and then a reference 2-4-day-old untreated platelets transfusion (Mirasol-Reference sequence).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference first, then Mirasol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This study arm will receive first a reference 2-4-day-old untreated platelets transfusion and then a 2-4-day-old Mirasol-treated platelets transfusion (Reference-Mirasol sequence).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2-4-day-old Mirasol-treated Platelets Transfusion</intervention_name>
    <description>2-4-day-old Mirasol-treated Platelets Units with:
Platelet yield between 2.4x10e11 and 4.5x10e11
Plasma carryover of &gt;32%
Cell count &gt; 800x103/µL</description>
    <arm_group_label>Mirasol first, then Reference</arm_group_label>
    <arm_group_label>Reference first, then Mirasol</arm_group_label>
    <other_name>Mirasol</other_name>
    <other_name>Pathogen Reduction</other_name>
    <other_name>PRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2-4-day-old Untreated Platelets Transfusion</intervention_name>
    <description>2-4-day-old Untreated Platelets Units with:
Platelet yield between 2.4x10e11 and 4.5x10e11
Plasma carryover of &gt;32%
Cell count &gt; 800x103/µL</description>
    <arm_group_label>Mirasol first, then Reference</arm_group_label>
    <arm_group_label>Reference first, then Mirasol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of age of 18 years or older.

          -  Have thrombocytopenia or expected to develop thrombocytopenia requiring at least 3
             platelet transfusions.

          -  Woman of child bearing potential must have a negative serum or urine pregnancy test
             within 72 hours before randomization.

          -  Subjects must have signed and dated the Informed Consent Form before performing any
             protocol related procedure.

        Exclusion Criteria:

          -  History of any hypersensitivity reaction to riboflavin or metabolites.

          -  History of refractoriness to platelet transfusions (defined as 2 successive
             CCI1hr&lt;5000) or presence of human leukocyte antigen (HLA) antibodies or positive
             lymphocytotoxicity or previously documented alloimmunization.

          -  Previous exposure to PRT-treated platelet concentrates.

          -  Active bleeding requiring one or more red cells concentrate transfusions (i.e. grade 3
             or 4 bleeding according to the WHO bleeding assessment scale in Appendix 1).

          -  Exposure to an investigational product, within 30 days before randomization.

          -  Splenomegaly (presence of a palpable spleen whose border could be felt more than 4 cm
             below the costal margin) or splenectomy.

          -  History or diagnosis of Immune/Idiopathic Thrombocytopenic Purpura (ITP), Thrombotic
             Thrombocytopenia Purpura (TTP), or Haemolytic Uremic Syndrome (HUS).

          -  Use of prohibited medication (see section 5.5).

          -  Pregnant or lactating females.

          -  Any medical condition or treatment that would be expected to compromise the
             effectiveness of a platelet transfusion or that would interfere with an expected
             platelet count increment.

          -  Any other medical condition that would compromise the participation of the subject in
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pär Johansson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transfusion Service Rigshospitalet - Dept of Immunology, Copenhagen Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lene Udby, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Service Rigshospitalet, Copenhagen Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematology Service Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Blegdamsvej</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Johansson PI, Simonsen AC, Brown PN, Ostrowski SR, Deberdt L, Van Hoydonck P, Yonemura SS, Goodrich RP. A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia. Transfusion. 2013 Sep;53(9):2043-52. doi: 10.1111/trf.12055. Epub 2012 Dec 24.</citation>
    <PMID>23278371</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2011</study_first_submitted>
  <study_first_submitted_qc>June 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <results_first_submitted>February 27, 2014</results_first_submitted>
  <results_first_submitted_qc>February 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2014</results_first_posted>
  <last_update_submitted>May 23, 2016</last_update_submitted>
  <last_update_submitted_qc>May 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mirasol</keyword>
  <keyword>Thrombocytopenic</keyword>
  <keyword>Pathogen reduction</keyword>
  <keyword>Platelets</keyword>
  <keyword>Thromboelastography</keyword>
  <keyword>CCI</keyword>
  <keyword>Corrected Count Increment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>16 patients enrolled versus 15 patients started: One patient was enrolled by error (exclusion criteria) and excluded after randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mirasol First, Then Reference</title>
          <description>This study arm received first a Mirasol treated 2-4-day-old platelet transfusion and then a reference 2-4-day-old platelet transfusion (Mirasol-Reference sequence).
Mirasol-treated Platelets: Mirasol-treated platelet units with:
Platelet yield between 2.4x10e11 and 4.5x10e11
Plasma carryover of &gt;32%
Cell count &gt; 800x103/µL</description>
        </group>
        <group group_id="P2">
          <title>Reference First, Then Mirasol</title>
          <description>This study arm received first a reference untreated 2-4-day-old platelet transfusion and then a Mirasol treated 2-4-day-old platelet transfusion (Reference-Mirasol sequence).
Mirasol-treated Platelets: Mirasol-treated platelet units with:
Platelet yield between 2.4x10e11 and 4.5x10e11
Plasma carryover of &gt;32%
Cell count &gt; 800x103/µL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Platelets Transfusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Platelets Transfusion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No need for additional transfusion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mirasol First, Then Reference</title>
          <description>This study arm will receive first a Mirasol treated 2-4-day-old platelet transfusion and then a reference 2-4-day-old platelet transfusion (Mirasol-Reference sequence).
Mirasol-treated Platelets: Mirasol-treated platelet units with:
Platelet yield between 2.4x10e11 and 4.5x10e11
Plasma carryover of &gt;32%
Cell count &gt; 800x103/µL</description>
        </group>
        <group group_id="B2">
          <title>Reference First, Then Mirasol</title>
          <description>This study arm will receive first a reference untreated 2-4-day-old platelet transfusion and then a Mirasol treated 2-4-day-old platelet transfusion (Reference-Mirasol sequence).
Mirasol-treated Platelets: Mirasol-treated platelet units with:
Platelet yield between 2.4x10e11 and 4.5x10e11
Plasma carryover of &gt;32%
Cell count &gt; 800x103/µL</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.13" spread="12.76"/>
                    <measurement group_id="B2" value="55.29" spread="19.95"/>
                    <measurement group_id="B3" value="57.33" spread="15.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Maximum Amplitude at 1-hour Post-transfusion</title>
        <description>Thromboelastography (TEG) Parameter: Pre- to post-transfusional modification of Maximum Amplitude at 1-hour post-transfusion</description>
        <time_frame>pre-transfusion, 1-hour post transfusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirasol</title>
            <description>Mirasol-treated 2-4-day old platelet transfusion</description>
          </group>
          <group group_id="O2">
            <title>Untreated Reference</title>
            <description>Untreated 2-4-day old platelet transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximum Amplitude at 1-hour Post-transfusion</title>
          <description>Thromboelastography (TEG) Parameter: Pre- to post-transfusional modification of Maximum Amplitude at 1-hour post-transfusion</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="7.0"/>
                    <measurement group_id="O2" value="15.4" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Maximum Amplitude at 24-hours Post-transfusion</title>
        <description>Thromboelastography parameter: Pre- to post-transfusional modification in Maximum Amplitude at 24-hours post-transfusion</description>
        <time_frame>pre-transfusion, 24-hour post transfusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirasol</title>
            <description>Mirasol-treated 2-4-day old platelet transfusion</description>
          </group>
          <group group_id="O2">
            <title>Untreated Reference</title>
            <description>Untreated 2-4-day old platelet transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximum Amplitude at 24-hours Post-transfusion</title>
          <description>Thromboelastography parameter: Pre- to post-transfusional modification in Maximum Amplitude at 24-hours post-transfusion</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="8.0"/>
                    <measurement group_id="O2" value="8.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours from start of transfusion</time_frame>
      <desc>Only transfusion related events</desc>
      <group_list>
        <group group_id="E1">
          <title>Mirasol-treated Platelets</title>
          <description>Patients that received a Mirasol treated 2-4-day-old platelet transfusion.</description>
        </group>
        <group group_id="E2">
          <title>Untreated Reference Platelets</title>
          <description>Patients that received an untreated reference2-4-day-old platelet transfusion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of subjects</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Pär Johansson</name_or_title>
      <organization>Transfusion Service Rigshospitalet - Dept of Immunology, Copenhagen Denmark</organization>
      <phone>+45 35452030</phone>
      <email>per.johansson@rh.regionh.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

